Over-expression of miR-106b promotes cell migration and metastasis in hepatocellular carcinoma by activating epithelial-mesenchymal transition process
about
The genetic and epigenetic alterations in human hepatocellular carcinoma: a recent updateMicroRNA-106b promotes colorectal cancer cell migration and invasion by directly targeting DLC1TAp63 suppress metastasis via miR-133b in colon cancer cells.miR-106b-25/miR-17-92 clusters: polycistrons with oncogenic roles in hepatocellular carcinomaUpregulation of microRNA-106b is associated with poor prognosis in hepatocellular carcinoma.miR-429 inhibits migration and invasion of breast cancer cells in vitro.MicroRNAs in the development and pathobiology of uterine leiomyomata: does evidence support future strategies for clinical intervention?miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma.Activation of platelet protease-activated receptor-1 induces epithelial-mesenchymal transition and chemotaxis of colon cancer cell line SW620.The PDGF-D/miR-106a/Twist1 pathway orchestrates epithelial-mesenchymal transition in gemcitabine resistance hepatoma cells.MiR-106b induces cell radioresistance via the PTEN/PI3K/AKT pathways and p21 in colorectal cancer.MicroRNA-451: epithelial-mesenchymal transition inhibitor and prognostic biomarker of hepatocelluar carcinoma.Down-regualtion of miR-106b induces epithelial-mesenchymal transition but suppresses metastatic colonization by targeting Prrx1 in colorectal cancer.MiR-195 is a key negative regulator of hepatocellular carcinoma metastasis by targeting FGF2 and VEGFA.Establishment of NOD/SCID mouse models of human hepatocellular carcinoma via subcutaneous transplantation of histologically intact tumor tissueRole of 3'-untranslated region translational control in cancer development, diagnostics and treatment.Integrative analysis of miRNA-mRNA and miRNA-miRNA interactions.ZIP4, a novel determinant of tumor invasion in hepatocellular carcinoma, contributes to tumor recurrence after liver transplantation.Multi-platform microRNA profiling of hepatoblastoma patients using formalin fixed paraffin embedded archival samples.Involvement of miR-106b in tumorigenic actions of both prolactin and estradiolEffect of miR-106b on Invasiveness of Pituitary Adenoma via PTEN-PI3K/AKT.MiR-106b inhibitors sensitize TRAIL-induced apoptosis in hepatocellular carcinoma through increase of death receptor 4.FGFR3 promotes angiogenesis-dependent metastasis of hepatocellular carcinoma via facilitating MCP-1-mediated vascular formation.Phosphorylation of nucleophosmin at threonine 234/237 is associated with HCC metastasis.MetastamiRs: A promising choice for antihepatocellular carcinoma nucleic acid drug development.MicroRNA-452 promotes tumorigenesis in hepatocellular carcinoma by targeting cyclin-dependent kinase inhibitor 1B.MicroRNA-106b targets FUT6 to promote cell migration, invasion, and proliferation in human breast cancer.miR-106b regulates the 5-fluorouracil resistance by targeting Zbtb7a in cholangiocarcinoma.Investigating the pretreatment miRNA expression patterns of advanced hepatocellular carcinoma patients in association with response to TACE treatment.MicroRNA expression and its detection in human supraglottic laryngeal squamous cell carcinoma.Alterations of miRNAs and Their Potential Roles in Arsenite-Induced Transformation of Human Bronchial Epithelial Cells.Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in hepatocellular carcinoma.Mir-452-3p: A Potential Tumor Promoter That Targets the CPEB3/EGFR Axis in Human Hepatocellular Carcinoma.Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC).MiR-106b promotes migration and invasion through enhancing EMT via downregulation of Smad 7 in Kazakh's esophageal squamous cell carcinoma.The miR-106b-25 cluster mediates breast tumor initiation through activation of NOTCH1 via direct repression of NEDD4L.miR-106b promotes cell invasion and metastasis via PTEN mediated EMT in ESCC.MicroRNA involvement in a metastatic non-functioning pituitary carcinoma.Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma.
P2860
Q27003050-AF760BC3-EF2F-4116-ADFC-A29BA0173EE2Q28384675-0695DC5C-9601-489F-A09F-7078C0C5B47CQ33555190-37C211FC-AAA5-4823-BF58-0738B0832CE0Q33661028-03447204-4752-4979-8FFD-5B64730811F6Q34667439-440FF861-0DE2-4CE9-A131-C524B048C039Q34775801-53029452-82B8-44A7-A58F-E168921D5579Q35140553-4D1E9B98-E2A4-4C43-9E07-8EF073998179Q35551941-251FABC5-C1AD-40D5-9492-76CBB06F34A7Q35605751-A7397821-AFEF-435C-BD67-01AEC2BD333DQ35740131-1BCA5BA2-1BF6-4FFF-8223-FB47D9B5E4A0Q35910713-9415E1D2-F317-4E4E-9F48-7302983BD18DQ36210961-4EF44F61-035D-4E46-94E8-AF2E88A99CD5Q36261431-4F263D72-156F-467D-97A5-5AC1ACBD71FDQ36464350-F078E519-EE53-4CB4-969A-002584E216A6Q36967467-D953CD11-5A65-484C-BEFF-FDE28CB760AAQ37617262-4EF36BBB-38DC-4E3B-AD9C-3E7D58864CE9Q37622025-92056D9D-B251-46C9-8528-8BF7187E7483Q37642348-41CB5AB6-7516-4829-BD41-C60FD2C696E8Q38383322-BE33DD11-9951-4AF2-90F5-F345CE623D7CQ38706936-D3DAB2A0-2A48-42F2-A86C-54066D46B7F2Q38712436-41BF0BEF-1918-4FB6-B007-3B7CB975E35AQ38730350-B313DE68-CE62-404F-9224-863F9BB249B3Q38780786-D3D5D0E2-C0DF-454D-92FA-9701A94F4133Q38822052-B3C6427F-869F-4FD7-9AAA-C1013A68D0FCQ38823802-BB43C25F-C962-43DD-82FE-C95373707624Q39038019-29C1401D-8E1F-47B3-B709-B237784EA5A8Q39494968-484D77AD-5CB1-427B-8FBD-8F27542EC1C4Q41592965-0087A350-182E-4054-9361-10CCC3CB786DQ41791058-AE6C436C-FD80-48CE-8B7C-4CB16C261A6EQ41928691-8BA1C0B0-B99D-4E84-A75A-12422038D92CQ42938861-E6ED7BB2-06B3-40CD-B84A-E82A32EC96DEQ48031390-D7D57B87-F1E4-4169-86DF-1810554BF27DQ49636117-0161733D-5D75-4A97-954D-820AE917E809Q49787968-39456F7E-B893-429F-9DA5-6370C74000A7Q51516495-898EC66B-17F8-4CAB-8177-E6E5A1976F36Q52584557-31C9D84E-1C8F-45CC-9BD1-991987C5F8BCQ52649778-62538D76-D9A6-4AF0-AED9-AC8E9636524FQ53547121-E737A43B-FEAE-4C4E-9AFB-981EA10274D8Q55378766-15B0D854-962B-4F63-B693-BB6A83E549F4
P2860
Over-expression of miR-106b promotes cell migration and metastasis in hepatocellular carcinoma by activating epithelial-mesenchymal transition process
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Over-expression of miR-106b pr ...... mesenchymal transition process
@ast
Over-expression of miR-106b pr ...... mesenchymal transition process
@en
Over-expression of miR-106b pr ...... mesenchymal transition process
@nl
type
label
Over-expression of miR-106b pr ...... mesenchymal transition process
@ast
Over-expression of miR-106b pr ...... mesenchymal transition process
@en
Over-expression of miR-106b pr ...... mesenchymal transition process
@nl
prefLabel
Over-expression of miR-106b pr ...... mesenchymal transition process
@ast
Over-expression of miR-106b pr ...... mesenchymal transition process
@en
Over-expression of miR-106b pr ...... mesenchymal transition process
@nl
P2093
P2860
P1433
P1476
Over-expression of miR-106b pr ...... mesenchymal transition process
@en
P2093
Ariel Ka Man Chow
Colin Siu Chi Lam
Jacky Yu Ki Chan
Jana Yim Hung Wo
Kevin Tak Pan Ng
Roberta Wen Chi Pang
Ronnie Tung Ping Poon
Sylvia Tsz Ching Chan
Wing Lung Yau
P2860
P304
P356
10.1371/JOURNAL.PONE.0057882
P407
P50
P577
2013-03-06T00:00:00Z